Efficacy and Safety of Pharmacologic Therapies in Nonobstructive Hypertrophic Cardiomyopathy: A Systematic Review
Journal of the American Heart Association · 03.11.2026 · 15 (21)
DOI: 10.1161/jaha.126.051256 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of the American Heart Association, erschienen am 03.11.2026. Verfasst von Shivam Patel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine University of Illinois College of Medicine Chicago IL USA. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Cardiovascular Agents. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background
Nonobstructive hypertrophic cardiomyopathy (HCM) affects approximately one‐third of all patients with HCM and carries substantial morbidity, yet no approved disease‐modifying therapies exist. We conducted a systematic review of prospective interventional studies evaluating pharmacologic therapies in adults with nonobstructive HCM.
Methods
A systematic search of PubMed, Cochrane Central Register of Controlled Trials, and Clinicaltrials.gov was performed through September 2025. Eligible studies included randomized and nonrandomized prospective interventional trials. A narrative synthesis was performed by pharmacologic class and outcome domain.
Results
Twenty‐nine clinical trials evaluating 9 pharmacologic classes were identified: cardiac myosin inhibitors, cardiac sarcomere modulators, metabolic modulators, angiotensin II receptor blockers, angiotensin receptor‐neprilysin inhibitors, mineralocorticoid receptor antagonists, SGLT2 (sodium‐glucose cotransporter 2) inhibitors, beta blockers, and calcium channel blockers. Cardiac myosin inhibitors demonstrated reductions in left ventricular hypertrophy, improvements in diastolic function, and marked reductions in cardiac biomarkers, although improvements in exercise capacity and symptoms were variable. SGLT2 inhibition showed concordant improvements in diastolic function, atrial remodeling, biomarkers, and functional status in patients with symptomatic nonobstructive HCM and comorbid type 2 diabetes. Angiotensin receptor blockade showed signals of structural remodeling with valsartan and candesartan without consistent functional benefit. Mineralocorticoid receptor antagonism and angiotensin receptor‐neprilysin inhibition demonstrated largely neutral effects. Among metabolic modulators, ninerafaxstat improved ventilatory efficiency and quality of life in patients with greater baseline symptom burden.
Conclusions
Pharmacologic responsiveness in nonobstructive HCM is variable and appears to be mechanism‐ and disease stage‐dependent. Ongoing trials evaluating cardiac myosin inhibitors, SGLT inhibitors, and novel therapeutic agents including ninerafaxstat and EDG‐7500 will be critical in further defining the therapeutic landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine University of Illinois College of Medicine Chicago IL USA.
- Midwestern University Chicago College of Osteopathic Medicine Downers Grove IL USA.
- Department of Cardiovascular Medicine Mayo Clinic Jacksonville FL USA.
ORCID-Profile: Shivam Patel, Akash Gandhi, Arman Pabani, Richa Shah, Pal Shah, Matthew W Martinez, Aakash Bavishi
Zitieren
APA
Patel, S., Gandhi, A., Pabani, A., Shah, R., Shah, P., Martinez, M. W., & Bavishi, A. (2026). Efficacy and Safety of Pharmacologic Therapies in Nonobstructive Hypertrophic Cardiomyopathy: A Systematic Review. Journal of the American Heart Association, 15(21). https://doi.org/10.1161/jaha.126.051256
Vancouver
Patel S, Gandhi A, Pabani A, Shah R, Shah P, Martinez MW, et al. Efficacy and Safety of Pharmacologic Therapies in Nonobstructive Hypertrophic Cardiomyopathy: A Systematic Review. Journal of the American Heart Association. 2026;15(21). doi:10.1161/jaha.126.051256
BibTeX
@article{Patel2026,
author = {Patel, Shivam and Gandhi, Akash and Pabani, Arman and Shah, Richa and Shah, Pal and Martinez, Matthew W and Bavishi, Aakash},
title = {Efficacy and Safety of Pharmacologic Therapies in Nonobstructive Hypertrophic Cardiomyopathy: A Systematic Review},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {21},
doi = {10.1161/jaha.126.051256}
}
EUVIMED